IN-VITRO SUSCEPTIBILITY OF PENICILLIN-RESISTANT STREPTOCOCCUS-PNEUMONIAE TO LEVOFLOXACIN, SELECTION OF RESISTANT MUTANTS, AND TIME-KILL SYNERGY STUDIES OF LEVOFLOXACIN COMBINED WITH VANCOMYCIN, TEICOPLANIN, FUSIDIC ACID, AND RIFAMPIN

Among 180 clinical isolates of pneumococci, no strains were found to b e resistant to levofloxacin (MIG, greater than or equal to 4 mu g/ml) whereas 9% were resistant to ofloxacin and 7% were resistant to ciprof loxacin. Synergism was demonstrated by time-kill studies in nine of ni ne strains for the combination of levofloxacin and vancomycin and in s ix of nine strains for levofloxacin plus teicoplanin. The combinations of levofloxacin with rifampin or fusidic acid were indifferent, Resis tant mutants could be selected using incremental concentrations of lev ofloxacin. For two of nine strains that were initially susceptible to levofloxacin, the MICs reached the resistance range (greater than or e qual to 4 mu g/ml). In contrast, ciprofloxacin and ofloxacin selected mutants from the susceptible to the resistant range more frequently (f our of six and six of seven strains, respectively), These data argue f or further study of levofloxacin against penicillin-resistant pneumoco cci.